Wall Street analysts forecast that Antares Pharma Inc (NASDAQ:ATRS) will post earnings of ($0.02) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Antares Pharma’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.04). Antares Pharma also posted earnings per share of ($0.02) in the same quarter last year. The business is expected to report its next quarterly earnings report on Tuesday, March 12th.
On average, analysts expect that Antares Pharma will report full year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.12) to ($0.09). For the next financial year, analysts expect that the company will report earnings of $0.04 per share, with EPS estimates ranging from ($0.09) to $0.21. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. Antares Pharma had a negative net margin of 27.84% and a negative return on equity of 59.08%. The business had revenue of $17.87 million during the quarter, compared to analyst estimates of $15.13 million.
Several equities research analysts recently issued reports on ATRS shares. BidaskClub upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Raymond James upped their price target on shares of Antares Pharma from $3.85 to $5.25 and gave the company a “strong-buy” rating in a report on Tuesday, October 2nd. HC Wainwright set a $5.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a research report on Monday, October 1st. Finally, Jefferies Financial Group upped their price target on shares of Antares Pharma to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Antares Pharma has a consensus rating of “Buy” and a consensus price target of $5.44.
In related news, Director Jacques Gonella sold 400,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $3.79, for a total transaction of $1,516,000.00. Following the completion of the transaction, the director now owns 9,585,848 shares in the company, valued at approximately $36,330,363.92. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. MML Investors Services LLC boosted its holdings in Antares Pharma by 92.4% during the third quarter. MML Investors Services LLC now owns 40,600 shares of the specialty pharmaceutical company’s stock worth $136,000 after buying an additional 19,500 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in Antares Pharma by 127.0% during the second quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after purchasing an additional 28,875 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Antares Pharma by 4.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 744,188 shares of the specialty pharmaceutical company’s stock valued at $1,921,000 after purchasing an additional 32,626 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Antares Pharma by 53.3% in the third quarter. MetLife Investment Advisors LLC now owns 109,970 shares of the specialty pharmaceutical company’s stock worth $369,000 after buying an additional 38,239 shares in the last quarter. Finally, JW Asset Management LLC lifted its stake in shares of Antares Pharma by 2.8% in the second quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock worth $4,697,000 after buying an additional 50,000 shares in the last quarter. Hedge funds and other institutional investors own 37.27% of the company’s stock.
Shares of NASDAQ ATRS traded down $0.02 on Thursday, reaching $3.16. 36,952 shares of the company’s stock traded hands, compared to its average volume of 1,052,083. Antares Pharma has a 12 month low of $1.75 and a 12 month high of $3.93. The company has a market capitalization of $500.98 million, a price-to-earnings ratio of -28.36 and a beta of 0.60. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.83 and a current ratio of 2.29.
About Antares Pharma
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.